| FSNUY Stock | | | USD 8.85 0.02 0.23% |
CEO
Dr. Francesco De Meo is Member of the Management Board and Chief Executive Officer of Business Segment Fresenius Helios at Fresenius SE Co KGaA since January 1, 2008. In 2000, Dr. De Meo became head of the legal and human resources departments of HELIOS Kliniken GmbH. On January 1, 2001, he was appointed to the HELIOS Kliniken Management Board with responsibilities for human resources, legal affairs, research and science. At the same time, he was also appointed Labor Relations Director. Before joining HELIOS, he was Director of Rauser AG, a management consultancy in Reutlingen, as well as a practicing Attorney. Currently, he serves as Chairman of the Supervisory Boards of Helios Beteiligungs AG and Helios Kliniken Schwerin GmbH. He studied Law and earned a Doctorate degree at Eberhard Karls Universitaet Tuebingen. since 2008.
| Age | 60 |
| Tenure | 16 years |
| Professional Marks | Ph.D |
| Phone | 49 6172 608 2487 |
| Web | https://www.fresenius.com |
Fresenius Management Efficiency
The company has return on total asset
(ROA) of
0.0292 % which means that it generated a profit of $0.0292 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.0793 %, meaning that it generated $0.0793 on every $100 dollars invested by stockholders. Fresenius' management efficiency ratios could be used to measure how well Fresenius manages its routine affairs as well as how well it operates its assets and liabilities.
Fresenius SE Co has accumulated 27.16
B in total debt with debt to equity ratio
(D/E) of 0.89, which is about average as compared to similar companies. Fresenius SE has a current ratio of 1.29, suggesting that it
is not liquid enough and may have problems paying out its financial obligations in time and when they become due. Debt can assist Fresenius until it has trouble settling it off, either with new capital or with free cash flow. So, Fresenius' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Fresenius SE sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Fresenius to invest in growth at high rates of return. When we think about Fresenius' use of debt, we should always consider it together with cash and equity.
KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Hhe, Germany. Fresenius operates under Medical Care Facilities classification in the United States and is traded on OTC Exchange. It employs 318647 people. Fresenius SE Co [FSNUY] is a
Pink Sheet which is traded through a dealer network over-the-counter (OTC).
Management Performance
Fresenius SE Leadership Team
Elected by the shareholders, the Fresenius' board of directors comprises two types of representatives: Fresenius inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Fresenius. The board's role is to monitor Fresenius' management team and ensure that shareholders' interests are well served. Fresenius' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Fresenius' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Francesco Meo, Member of the Management Board - Fresenius Management SE and CEO of Fresenius Helios | |
| Michael Sen, Pres CEO | |
| Sara Hennicken, Chief Officer | |
| Helen Giza, Member SE | |
| Ernst Wastler, Member of the Management Board - Fresenius Management SE and CEO of Fresenius Vamed | |
| Sebastian Biedenkopf, HR, Officer | |
| Matthias Link, Sr Communications | |
| Markus Georgi, Senior Vice President Investor Relations | |
| Carla Kriwet, Members SE | |
Fresenius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Fresenius a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Fresenius Pink Sheet Analysis
When running Fresenius' price analysis, check to
measure Fresenius' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fresenius is operating at the current time. Most of Fresenius' value examination focuses on studying past and present price action to
predict the probability of Fresenius' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fresenius' price. Additionally, you may evaluate how the addition of Fresenius to your portfolios can decrease your overall portfolio volatility.